Want to see JP:2370 full AI Analyst Report?
2370 Stock Chart & Stats
¥29.00
-¥1.00(-2.70%)
At close: 4:00 PM EST
¥29.00
-¥1.00(-2.70%)
Day’s Range― - ―
52-Week Range¥23.00 - ¥43.00
Previous CloseN/A
Volume258.10K
Average Volume (3M)1.57M
Market Cap
¥7.04B
Enterprise Value¥4.04B
Total Cash (Recent Filing)¥5.03B
Total Debt (Recent Filing)¥91.32M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.29
Shares Outstanding281,667,330
10 Day Avg. Volume1,137,840
30 Day Avg. Volume1,567,416
Financial Highlights & Ratios
PEG Ratio-3.11
Price to Book (P/B)2.45
Price to Sales (P/S)11.43
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSustained top-line growth in FY2025 indicates continued demand for MEDINET’s services and expanding project volume. For a services business built on multi-month contracts, this trend supports operational scale, improves utilization potential and provides a pathway to recover margins if cost discipline and mix improve over several quarters.
Low Financial LeverageA conservatively levered balance sheet reduces near-term solvency and interest-service risk, giving management flexibility to fund operations, absorb cash burn or pursue strategic investments. Low leverage is a durable advantage during earnings volatility and lengthens the runway before external financing is required.
Business Model & Structural DemandMEDINET’s fee-based CRO/support model benefits from secular outsourcing in pharma and life-sciences. Multi-month to multi-year contracts and diversified client types (pharma, medical institutions, CROs) create recurring revenue characteristics and structural demand that sustain activity regardless of short-term market swings.
Bears Say
Persistent Large LossesVery large and persistent net losses materially impair earnings quality and delay path to sustainable profitability. Over multiple reporting periods this erodes internal funding, limits reinvestment in higher-margin services, and increases the probability the firm will need dilutive or costly external capital to continue operations.
Weak Cash Generation / Cash BurnConsistent negative operating and free cash flow means reported losses translate into real cash outflows, reducing runway. Persistent cash burn forces reliance on financing or cuts to growth initiatives, raises liquidity and execution risk, and limits the company’s ability to invest in staffing, systems, or new service capabilities.
Declining Margins And Equity ErosionA sharp long-term decline in gross margin indicates deteriorating pricing power or worsening cost structure, while meaningful equity reduction reflects accumulated losses. Together these trends shrink the financial buffer, constrain borrowing capacity, and reduce management’s flexibility to pursue strategic investments without external capital.
MEDINET Co., Ltd. News
2370 FAQ
What was MEDINET Co., Ltd.’s price range in the past 12 months?
MEDINET Co., Ltd. lowest stock price was ¥23.00 and its highest was ¥43.00 in the past 12 months.
What is MEDINET Co., Ltd.’s market cap?
MEDINET Co., Ltd.’s market cap is ¥7.04B.
When is MEDINET Co., Ltd.’s upcoming earnings report date?
MEDINET Co., Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 10 days.
How were MEDINET Co., Ltd.’s earnings last quarter?
MEDINET Co., Ltd. released its earnings results on May 13, 2026. The company reported -¥0.78 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.78.
Is MEDINET Co., Ltd. overvalued?
According to Wall Street analysts MEDINET Co., Ltd.’s price is currently Overvalued.
Does MEDINET Co., Ltd. pay dividends?
MEDINET Co., Ltd. does not currently pay dividends.
What is MEDINET Co., Ltd.’s EPS estimate?
MEDINET Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MEDINET Co., Ltd. have?
MEDINET Co., Ltd. has 281,667,330 shares outstanding.
What happened to MEDINET Co., Ltd.’s price movement after its last earnings report?
MEDINET Co., Ltd. reported an EPS of -¥0.78 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MEDINET Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2370
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MEDINET Co., Ltd.
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
Technical Analysis
Linical Co., Ltd.
―
Trans Genic Inc.
―
Soiken Holdings Inc.
―
―
PRISM BioLab Co. LTD
―